Wang Yilai, Yan Zhaoping, Huang Yile, Qiu Cailing, Chen Xiangyun, Hu Ying, Meng Qingyong, Wei Jun
Laboratory for Nursing Science & Institute of Laboratory Medicine, Guangdong Medical University Dongguan 523808, China.
Ocean University of ChinaQingdao 266033, China; Sixth People's Hospital of QingdaoQingdao 266033, China.
Am J Cancer Res. 2017 Mar 1;7(3):603-609. eCollection 2017.
Natural antibodies have been found to have anti-tumorigenic function. This study was designed to investigate whether natural IgG antibodies against vascular endothelial growth factor receptor 1 (VEGFR1) could suppress the growth of hepatocellular carcinoma (HCC) cells. Three HCC cell lines and A549 lung cancer cells were used for this study. They were grown, respectively, with human plasma positive or negative for anti-VEGFR1 IgG. Cell viability, apoptosis and VEGFR1 gene expression were examined. Three patients with HCC were recruited for a case study. The results showed that plasma anti-VEGFR1 IgG significantly inhibited the proliferation of all three HCC cell lines but not A549 cell line; the proportions of apoptotic cells were significantly higher in HCC cells treated with anti-VEGFR1 IgG positive plasma than those treated with IgG negative plasma. The expression of the VEGFR1 gene was significantly higher in HCC cells than A549 cells. Of three HCC patients who received transfusion of anti-VEGFR1 IgG positive plasma, two cases with stage B showed a good response to the treatment but one with distant metastasis did not. Human plasma IgG against VEGFR1 may be a promising agent for anti-HCC therapy.
已发现天然抗体具有抗肿瘤功能。本研究旨在调查抗血管内皮生长因子受体1（VEGFR1）的天然IgG抗体是否能抑制肝癌（HCC）细胞的生长。本研究使用了三种肝癌细胞系和A549肺癌细胞。它们分别在抗VEGFR1 IgG呈阳性或阴性的人血浆中培养。检测细胞活力、凋亡情况以及VEGFR1基因表达。招募了三名肝癌患者进行病例研究。结果显示，血浆抗VEGFR1 IgG显著抑制了所有三种肝癌细胞系的增殖，但对A549细胞系无抑制作用；用抗VEGFR1 IgG阳性血浆处理的肝癌细胞中凋亡细胞的比例显著高于用IgG阴性血浆处理的细胞。肝癌细胞中VEGFR1基因的表达显著高于A549细胞。在接受抗VEGFR1 IgG阳性血浆输血的三名肝癌患者中，两名B期患者对治疗反应良好，但一名有远处转移的患者无反应。抗VEGFR1的人血浆IgG可能是一种有前景的抗肝癌治疗药物。
